Pneumococcal conjugate vaccine introduction in Latin America and the Caribbean: progress and lessons learned
Nenhuma Miniatura disponível
Data
2016
Título da Revista
ISSN da Revista
Título de Volume
Editor
Resumo
In Latin America and the Caribbean, pneumococcus has been estimated to cause 12,000-28,000 deaths, 182,000 hospitalizations, and 1.4 million clinic visits annually. Countries in the Americas have been among the first developing nations to introduce pneumococcal conjugate vaccines into their Expanded Programs on Immunization, with 34 countries and territories having introduced these vaccines as of September 2015. Lessons learned for successful vaccine introduction include the importance of coordination between political and technical decision makers, adjustments to the cold chain prior to vaccine introduction, and the need for detailed plans addressing the financial and technical sustainability of introduction. Though many questions on the Pneumococcal Conjugate Vaccine remain unanswered, the experience of the Americas suggests that the vaccines can be introduced quickly and effectively.
Descrição
Palavras-chave
Peumococcus, New vaccines, Pneumonia, Surveillance, Pneumococcal, Conjugate vaccines
Citação
OLIVEIRA, Lucia Helena de et al. Pneumococcal conjugate vaccine introduction in Latin America and the Caribbean: progress and lessons learned. Expert Review of Vaccines, Abingdon, v. 15, n. 10, p. 1295-1304, 2016. DOI: 10.1586/14760584.2016.1166961. Disponível em: https://www.tandfonline.com/doi/10.1586/14760584.2016.1166961?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed. Acesso em: 4 dez. 2024.